Efektivitas Pemberian Bisacodyl terhadap Laju Penurunan Dosis Iodium-131 pada Pasien Kanker Tiroid
di RSUP Dr. Sardjito
Angelica Suci Kalyanaputri, Ir. Fitrotun Aliyah, S.T., M.T., Ph.D. ; dr. Hanif Afkari, Sp.KN-TM, Sub.Sp.Onk(K)
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

[1] M. Clerc *et al.*, "The Role of Iodine-131 in the Treatment and Management of Thyroid Cancer," *Clinical and Translational Imaging*, 2025.

[2] J. Wadsley *et al.*, "Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK," *Clinical Oncology*, vol. 35, 2023.

[3] A. Fugazzola *et al.*, "The Potential Interaction Between Medical Treatment and Radioiodine Treatment Success: A Systematic Review," *Frontiers in Endocrinology*, 2023.

[4] H. Kato *et al.*, "Clinical Factors Affecting Colonic Iodine-131 Distribution After Radioactive Iodine Therapy for Thyroid Cancer," *Annals of Nuclear Medicine*, 2025.

[5] N. Takata *et al.*, "Clinical factors affecting colonic iodine-131 distribution after radioactive iodine therapy for thyroid cancer," *Japanese Journal of Radiology*, vol. 44, no. 4, pp. 394–401, 2026.

[6] M. Corsetti, S. Landes, and R. Lange, "*Bisacodyl*: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation," *Neurogastroenterology & Motility*, vol. 33, no. 10, Art. no. e14123, Oct. 2021.

[7] R. Ravichandran, J. P. Binukumar, and A. Al Saadi, "Estimation of effective half life of clearance of radioactive Iodine (^{131}I) in patients treated for hyperthyroidism and carcinoma thyroid," *Indian Journal of Nuclear Medicine*, vol. 25, no. 2, pp. 49–52, Apr.–Jun. 2010, doi: 10.4103/0972-3919.72686.

[8] M. Klain *et al.*, "Whole-body radioiodine effective half-life in patients with differentiated thyroid cancer," *Diagnostics*, vol. 11, no. 10, Art. no. 1740, Sep. 2021.

[9] E. B. Podgoršak, *Radiation Physics for Medical Physicists*, 3rd ed. Cham, Switzerland: Springer, 2016.

[10] J. Dumont, R. Opitz, D. Christophe, G. Vassart, P. P. Roger, and C. Maenhaut, "Ontogeny, Anatomy, Metabolism and Physiology of the Thyroid," in Endotext, K. R. Feingold, B. Anawalt, and A. Boyce, Eds. South Dartmouth, MA: MDText.com, Inc., 2011.

[11] F. Miot, C. Dupuy, J. E. Dumont, and B. A. Rousset, "Chapter 2: Thyroid Hormone Synthesis and Secretion," in *Endotext*, K. R. Feingold, B. Anawalt,

Efektivitas Pemberian Bisacodyl terhadap Laju Penurunan Dosis Iodium-131 pada Pasien Kanker Tiroid
di RSUP Dr. Sardjito
Angelica Suci Kalyanaputri, Ir. Fitrotun Aliyah, S.T., M.T., Ph.D. ; dr. Hanif Afkari, Sp.KN-TM, Sub.Sp.Onk(K)
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

and A. Boyce, Eds. South Dartmouth, MA: MDText.com, Inc., 2012.

[12] S. Mariotti and P. Beck-Peccoz, "Physiology of the Hypothalamic-Pituitary-Thyroid Axis," in *Endotext*, K. R. Feingold, B. Anawalt, and A. Boyce, Eds. South Dartmouth, MA: MDText.com, Inc., 2021.

[13] National Cancer Institute, *What You Need To Know About™ Thyroid Cancer*. U.S. Department of Health and Human Services, 2020.

[14] J. A. Fagin and S. A. Wells, "Biologic and Clinical Perspectives on Thyroid Cancer," in *Endotext*, K. R. Feingold, B. Anawalt, M. R. Blackman, et al., Eds. South Dartmouth, MA: MDText.com, Inc., 2016

[15] L. M. Demers and C. A. Spencer, "Laboratory Medicine Practice Guidelines: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease," in *Endotext*. South Dartmouth, MA: MDText.com, Inc., 2022.

[16] L. F. Pan, C. Y. Chiang, C. C. Huang, H. T. Kao, C. F. Chen, B. R. Peng, and L. K. Pan, "Thyroid biokinetics for radioactive Iodium-131 in twelve thyroid cancer patients via the refined nine-compartmental model," *Applied Sciences*, vol. 12, no. 11, Art. no. 5538, May 2022

[17] International Atomic Energy Agency, *Release of Patients After Radionuclide Therapy*, Safety Reports Series No. 63, Vienna: IAEA, 2009, pp. 1-13, 19-21, 23-27, 48-51, 53-54, 60-63, 68-71.

[18] International Atomic Energy Agency, *Nuclear Medicine in Thyroid Cancer Management: A Practical Approach*, IAEA-TECDOC-1608, Vienna: IAEA, 2009, pp. 63-65, 70-71, 79-81, 85-87, 107-113, 119-121, 140-144.

[19] F. Pacini and L. J. De Groot, "Thyroid Cancer," in *Endotext*, S. Refetoff, L. J. De Groot, et al., Eds. South Dartmouth, MA: MDText.com, Inc., 2013, pp. 1-4, 13-16, 19-22, 31-36, 42-44.

[20] D. Hardiansyah, A. Riana, H. Hänscheid, J. M. Jabar, A. J. Beer, M. Lassmann, and G. Glatting, "131I therapy for benign thyroid disease: flexible single-time-point dosimetry using population-based model selection with non-linear mixed-effects modelling," *EJNMMI Physics*, vol. 12, p. 806, 2025

[21] L. F. Pan, C. Y. Chiang, C. C. Huang, H. T. Kao, C. F. Chen, B. R. Peng, and L. K. Pan, "Thyroid biokinetics for radioactive Iodium-131 in twelve thyroid cancer patients via the refined nine-compartmental model," *Applied Sciences*, vol. 12, no. 11, p. 5538, 2022

[22] M. Andersson and S. Mattsson, "Improved patient dosimetry at radioiodine therapy by combining the ICRP compartment model and the EANM pre-therapeutic standard procedure for benign thyroid diseases," *Frontiers in*

Efektivitas Pemberian Bisacodyl terhadap Laju Penurunan Dosis Iodium-131 pada Pasien Kanker Tiroid
di RSUP Dr. Sardjito
Angelica Suci Kalyanaputri, Ir. Fitrotun Aliyah, S.T., M.T., Ph.D. ; dr. Hanif Afkari, Sp.KN-TM, Sub.Sp.Onk(K)
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Endocrinology, vol. 12, p. 634955, 2021

[23] V. Topić Vučenović, Z. Rajkovača, D. Jelić, D. Stanimirović, G. Vuleta, B. Miljković, and K. Vučićević, "Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach," *European Journal of Clinical Pharmacology*, vol. 74, no. 8, pp. 1037–1045, 2018

[24] P. Whorwell, R. Lange, and C. Scarpignato, "Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge," *Therapeutic Advances in Gastroenterology*, vol. 17, pp. 1–18, 2024.

[25] L. Chang, W. D. Chey, A. Imdad, C. V. Almario, A. E. Bharucha, S. Diem, K. B. Greer, B. Hanson, L. A. Harris, C. Ko, M. H. Murad, A. Patel, E. D. Shah, A. J. Lembo, and S. Sultan, "American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation," *The American Journal of Gastroenterology*, vol. 118, no. 6, pp. 936–954, June 2023.

[26] Badan Pengawas Tenaga Nuklir (BAPETEN), *Peraturan Badan Pengawas Tenaga Nuklir Nomor 3 Tahun 2023 tentang Keselamatan Radiasi pada Terapi Radionuklida*, Jakarta: BAPETEN, 2023.

[27] E. Hiswara, N. Nuraeni, N. R. Hidayati, D. Kartikasari, H. T. Utami, S. Ulya, O. A. Firmansyah, dan A. F. Jundi, *Proteksi Radiasi pada Terapi Radionuklida*, Jakarta: Penerbit BRIN, 2025, ch. 4, pp. 21–45.

[28] International Atomic Energy Agency (IAEA), *Radiation Protection and Safety in Medical Uses of Ionizing Radiation*, IAEA Safety Standards Series No. SSG-46, Vienna: IAEA, 2018, pp. 65–89.

[29] A. Ifrah, J. Kanaparthi, R. Fromer, A. H. Gayner, A. H. Maurer, S. Dadparvar, and H. P. Parkman, "Whole Gut Transit Scintigraphy for the Assessment of Patients with Symptoms of Chronic Constipation," *Digestive Diseases and Sciences*, vol. 69, pp. 3875–3881, Aug. 2024.

[30] L. Pesce and P. Kopp, "Iodide transport: implications for health and disease," *International Journal of Pediatric Endocrinology*, vol. 2014, no. 8, pp. 1–18, 2014.

[31] International Commission on Radiological Protection (ICRP), "Release of patients after therapy with unsealed radionuclides," *Annals of the ICRP (ICRP Publication 94)*, vol. 34, no. 2, pp. 1–79, 2004.

[32] L. Kääriä, M. Lapela, M. Seppänen, M. Högerman, J. Ruohola, A. Ålgars, and T. Noponen, "Determination of effective half-life of ^{131}I in thyroid cancer patients using remote dose-rate meter," *EJNMMI Physics*, vol. 11, no. 101,

UNIVERSITAS GADJAH MADA
Efektivitas Pemberian Bisacodyl terhadap Laju Penurunan Dosis Iodium-131 pada Pasien Kanker Tiroid di RSUP Dr. Sardjito
Angelica Suci Kalyanaputri, Ir. Fitrotun Aliyah, S.T., M.T., Ph.D. ; dr. Hanif Afkari, Sp.KN-TM, Sub.Sp.Onk(K)
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

pp. 1–13, Nov. 2024.

[33] P. S. Sundaram, S. Padma, S. b Sudha, and K. c Sasikala, “Transient cytotoxicity of 131I beta radiation in hyperthyroid patients treated with radioactive iodine.,” *Indian Journal of Medical Research*, vol. 133, no. 4, pp. 401–406, Apr. 2011.

[34] A. E. Stanciu, A. Verzia, M. M. Stanciu, A. Zamfirescu, and D. C. Gheorghe, “Analysis of the Correlation between the Radioactive Iodine Activity and Neutrophil-to-Lymphocyte Ratio in Patients with Differentiated Thyroid Cancer,” *Cancers*, vol. 14, no. 8, pp. 1899–1899, Apr. 2022.

[35] M. Uchiyama, G. Tanaka, and S. Akiba, “Radioiodine Retention by 2 Japanese Male Adults After A Single Oral Dose,” *Journal of Radiation Research*, vol. 23, no. 3, pp. 358–370, Sept. 1982.

[36] M. Demir et al., “The evaluation of urine activity and external dose rate from patients receiving radioiodine therapy for thyroid cancer,” *Radiation Protection Dosimetry*, vol. 156, no. 1, pp. 25–29, Aug. 2013.

[37] S. Takahashi, D. T. B. Thuy, H. Sato, Y. Kubota, X.-Z. Sun, and N. V. Chandrasekharan, “Effects of the restriction of food and water intake on the distribution and retention of radioiodine in mice.,” *Journal of Radiation Research*, vol. 41, no. 3, pp. 313–320, Sept. 2000.

[38] A. Garrocho-Rangel, S. Aranda-Romo, R. Martínez-Martínez, V. Zavala-Alonso, J. C. Flores-Arriaga, and A. Pozos-Guillén, "Fundamentals of nonparametric statistical tests for dental clinical research," *Dent. J.*, vol. 12, no. 10, art. no. 314, Sep. 2024.

[39] S. Parab and S. Bhalerao, "Choosing statistical test," *Int. J. Ayurveda Res.*, vol. 1, no. 3, pp. 187–191, Jul.–Sep. 2010.

[40] R. L. Wasserstein and N. A. Lazar, "The ASA statement on p-values: Context, process, and purpose," *The American Statistician*, vol. 70, no. 2, pp. 129–133, 2016.